Document Type

Article

Publication Date

5-2023

Abstract

Highlights

  • To measure 18 intracellular proteins in blood cells of bipolar depressed patients and healthy controls;

  • TFour proteins in monocytes and 2 proteins in CD4+ T Cells were significantly lower in patients than in healthy controls;

  • The studied proteins are involved in prolactin, leptin, BDNF, and interleukin-3 signal pathways;

  • Studying intracellular proteins with enhanced flow cytometry may find biomarkers differentiating bipolar disorder from healthy controls.

Abstract

Background

Molecular biomarkers for bipolar disorder (BD) that distinguish it from other manifestations of depressive symptoms remain unknown. The aim of this study was to determine if a very sensitive tyramine-based signal-amplification technology for flow cytometry (CellPrint™) could facilitate the identification of cell-specific analyte expression profiles of peripheral blood cells for bipolar depression (BPD) versus healthy controls (HCs).

Methods

The diagnosis of psychiatric disorders was ascertained with Mini International Neuropsychiatric Interview for DSM-5. Expression levels for eighteen protein analytes previously shown to be related to bipolar disorder were assessed with CellPrint™ in CD4+ T cells and monocytes of bipolar patients and HCs. Implementation of protein-protein interaction (PPI) network and pathway analysis was subsequently used to identify new analytes and pathways for subsequent interrogations.

Results

Fourteen drug-naïve or -free patients with bipolar I or II depression and 17 healthy controls (HCs) were enrolled. The most distinguishable changes in analyte expression based on t-tests included GSK3β, HMGB1, IRS2, phospho-GSK3αβ, phospho-RELA, and TSPO in CD4+ T cells and calmodulin, GSK3β, IRS2, and phospho-HS1 in monocytes. Subsequent PPI and pathway analysis indicated that prolactin, leptin, BDNF, and interleukin-3 signal pathways were significantly different between bipolar patients and HCs.

Limitation

The sample size of the study was small and 2 patients were on medications.

Conclusion

In this pilot study, CellPrint™ was able to detect differences in cell-specific protein levels between BPD patients and HCs. A subsequent study including samples from patients with BPD, major depressive disorder, and HCs is warranted.

Comments

Original published version available at https://doi.org/10.1016/j.jad.2023.02.058

Publication Title

Journal of Affective Disorders

DOI

10.1016/j.jad.2023.02.058

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.